However, we did see different patterns
of estrogen activity change according to participants» body mass index (BMI).
Not exact matches
One
of the concerns is that phytoestrogens, especially isoflavones, may have
estrogen - like
activity.
Researchers in England have found that in trace amounts, they activate
estrogen receptors in cells, which in turn alters the
activity of certain genes.
These smooth and sweet cuties pack some serious phytoestrogens, which mimic the
activity of estrogen in the body.
Using in vitro, or test tube, experiments, the researchers applied these chemicals to human cancer cells to measure changes
of estrogen receptor - and androgen receptor - target genes and transcriptional
activity.
«We found bazedoxifene binds to the
estrogen receptor and interferes with its
activity, but the surprising thing we then found was that it also degrades the receptor; it gets rid
of it,» said senior author Donald McDonnell, PhD, chair
of Duke's Department
of Pharmacology and Cancer Biology.
Gorelick, the lead author, Halpern and Alice Hung
of Carnegie, along with Luke Iwanowicz and Vicki Blazer
of the Fish Health Branch
of the U.S. Geological Survey, used genetically modified zebrafish that show
estrogen receptor
activity on a cell's DNA.
Elevated exposure to
estrogen over a long period is linked with higher breast cancer rates in adulthood and earlier onset
of risky sexual
activity.
Injection
of estrogens (17β - estradiol or diethylstilbestrol) into immature chicks results in a marked (30 - to 50-fold) increase in the ornithine decarboxylase
activity of oviductal homogenates within a 4 - hour period.
An elevation
of decarboxylase
activity was obtained in vitro when oviducts from immature chicks were incubated in the presence
of estrogen.
Then, they added
estrogen to see if gene
activity changed, honing in on TLR8, an X chromosome - linked gene whose expression has already been implicated in the development
of lupus.
The researchers experimentally manipulated
estrogen levels over several months in healthy women with both versions
of the gene while monitoring their brain
activity as they performed a working memory task.
Enlarged male breasts, or gynecomastia, result from an imbalance between the
activity of estrogens, which stimulate breast growth, and
estrogen - inhibiting androgens.
Gwendolyn Thomas, assistant professor
of exercise science, is the co-author
of a groundbreaking article in the Obesity Journal (The Obesity Society, 2017) about the effects
of exercise and physical
activity on postmenopausal breast cancer survivors taking AIs — hormone - therapy drugs that stop the production
of estrogen.
«We found that if we exposed mice to one
of two common endocrine disruptors - bisphenol A (BPA) or ethinyl estradiol (EE), which is the
estrogen present in birth control pills, during development, it caused later disruptions in voluntary physical
activity once the mice became adults,» said Cheryl Rosenfeld, associate professor
of biomedical sciences in the College
of Veterinary Medicine and a researcher in the Bond Life Sciences Center at MU.
BPA is believed to exert its biological effects largely through loose occupancy
of the
estrogen receptor, and there are reports
of both
estrogen agonist [7] and androgen antagonist [8]
activity.
«Our data further suggest that, despite the historical bias toward the effects
of estrogen on the
estrogen receptor, it's the progesterone receptor that dominantly controls
estrogen receptor
activity when both receptors are present and activated.»
Women's Health Initiative researchers found a relationship between obesity, physical
activity and triple - negative breast cancer, a subtype
of breast cancer characterized by a lack
of estrogen, progesterone and HER2 expression.
Its chemical structure is similar to that
of bisphenol A (BPA), and like BPA, is can mimic the
activity of estrogen, a female sex hormone.
Estrogen and androgen receptor
activities of hydraulic fracturing chemicals and surface and ground water in a drilling - dense region.
Recent estimates suggest that as many as 1.9 million children younger than 18 years have a sport - or recreation - related concussion each year in the United States.1 This injury is biomechanically induced, with symptoms resulting from neuronal dysfunction due to functional and neurometabolic alterations rather than gross structural abnormalities.2 Compared with boys involved in similar
activities, girls experience higher rates
of sport - related concussion,3 - 7 report more severe symptoms,8 - 11 demonstrate worse cognitive impairment,8 - 10, 12 and take longer to recover.11 The neural mechanisms behind these postconcussion sex differences are poorly understood but have been attributed to differences in neuroanatomy and physiology, 13 cerebral blood flow, 14 and the female sex hormones
estrogen and progesterone.15 - 17
The
activity of mPOA neurotensin neurons was more intense in female mice that had high
estrogen levels or a mixture
of estrogen and progesterone, which shoots up before they become fertile.
Susan Amara, USA - «Regulation
of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation
of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses
of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology
of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy
of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis
of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms
of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect
of beta adrenergic stimulation; cardiovascular function
of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and
Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) tran
Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation
of Vascular Tone, Adipose Tissue Regulation
of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization
of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions
of Biologically Active Components
of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology
of G protein - coupled receptors, in particular opioid receptors, regulation
of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design
of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors
of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution
of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin,
estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) tran
estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation
of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function
of GABA - A receptors; mode
of action
of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA -
Activity and regulation
of expression and function
of the ATP - binding cassette (ABC) transporters
New research from Emory University School
of Medicine and Harvard Medical School provides insight into how
estrogen changes gene
activity in the brain to achieve its protective effects.
On the other hand, some scientific evidence hints that higher levels
of estrogen lead to an increased
activity of the alpha - adrenergic receptors in the lower part
of the body, which slow fat release and are the reason why many women have a pear shape fat distribution.
Soy may also mimic the
activity of the hormone
estrogen in your body and can interfere with hormonal and overall thyroid function.
Even low exposures
of BPA, for example, a common chemical in plastics, can increase our risk
of breast cancer because it has
estrogen - mimicking biological
activity.
This is partly due to reduction in the production
of hormones such as testosterone, human growth hormone and
estrogen and also because
of lack
of weight - bearing
activity.
The biological
activity of estrogen and testosterone, the sex hormones
of the body, which are believed to play a part in type 2 diabetes development are regulated by a protein known as SHBG (sex hormone - binding globulin).
«A high level
of circulating insulin could interfere with sex hormone
activity and boost
estrogen levels, both
of which might increase the number
of menstrual cycles and deplete egg supply faster, thus causing an earlier menopause.»
Consuming alcohol in big quantities has been correlated to boosting the
activity of aromatization which is the process in which testosterone is converted into
estrogen.
In addition, not only are some
of them
estrogen mimickers, but others will suppress your enzymatic
activity necessary to produce androgen hormones, while other will block the receptor sites on the cell.
Estrogen reduces endothelial progenitor cell senescence through augmentation
of telomerase
activity.
They can mimic the action
of estrogen produced in cells and can alter hormonal
activity in women and men.
Some research has focused on parabens, which are preservatives used in some deodorants and antiperspirants that have been shown to mimic the
activity of estrogen in the body's cells.
These
estrogen mimickers not only affect the balance
of estrogen to progesterone in our body but also affect
estrogen metabolism and alter hormone
activity.
BCPs can for that reason 1) raise
estrogen levels — which either corrects an
estrogen deficiency or helps balance the
activity of runaway testosterone — and they can also 2) restore proper balance between
estrogen and progesterone, which is important for keeping progesterone levels within their proper parameters.
If despite carefully increasing doses
of bio-identical
estrogens, your patient is still experiencing hot flushes and other menopausal symptoms suggestive
of insufficient
estrogen (e.g., night sweats, insomnia, memory and concentration difficulties, anxiety), she may be hyperexcreting
estrogen due to upregulated Phase I (the cytochrome P450 family
of enzymes)
activity.
The blood
activities after formation
of the healthy 2 - hydroxy
estrogens were compared to those
of 4 - hydroxy
estrogen.
The reasoning goes as follows:
estrogen is a sex hormone that is essential to female bone health because it promotes the
activity of osteoblasts, which are cells that produce bone.
EstroQuench ™ is used by healthcare professionals to reduce
estrogens levels by inhibiting aromatase
activity, which will decrease the conversion
of androgens (testosterone and androstenedione) to
estrogens (estradiol and estrone).
BHRT supports healthy sexual
activity in women by restoring depleted levels
of testosterone and
estrogen, thereby restoring sexual interest to previous levels.
Balanced digestive flora also reduces the
activity of an enzyme called beta - glucaronidase, which is linked to
estrogen - related cancers.
In vivo, breast cancer growth is regulated by
estrogens and peptide growth factors, such as epidermal growth factor (EGF), the receptor
of which has intrinsic PTK
activity.
This aromatase
activity is the enzymatic conversion
of androsterone and testosterone into estradiol, more commonly known as E2 or
estrogen.
Around the time
of ovulation,
estrogen causes changes in the vaginal mucus, making it more tolerant
of male penetration during sexual
activity and more hospitable to sperm.
When we have high levels
of estrogen, it generally means that we have lower levels
of testosterone and higher levels
of what is called aromatase
activity.
First, we adjusted for age (in y), cigarette smoking (yes or no), physical
activity (continuous), current
estrogen use (yes or no), menopausal status (yes or no), socioeconomic status (categorical), family history
of diabetes and stroke (yes or no), and systolic and diastolic blood pressures (continuous).
C - Reactive Protein levels fluctuate from day to day, and levels increase with aging, high blood pressure, alcohol use, smoking, low levels
of physical
activity, chronic fatigue, coffee consumption, having elevated triglycerides, insulin resistance and diabetes, taking
estrogen, eating a high protein diet, and suffering sleep disturbances, and depression.
Low thyroid
activity can also be a result
of other things, such as chronic stress or excess
estrogen.